Gilead Sciences
Budget
€1 — €0
EP Access
2
accredited persons
Staff
4
2.2 FTE
EU Grants
None
Mission & Goals
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 38 countries worldwide.
EU Legislative Interests
EU initiatives relevant to HIV/AIDS, Hepatitis / Liver diseases, Cell Therapies and oncology - ATMP Regulation - EU IP policy - EU research policy - EU trade policy - Health Systems Performance Assessment - Health Technology Assessment & Market Access - Industrial policy - Outcomes-based healthcare systems - General Pharmaceutical Legislation - EU Biotech Act - Digital Health - Europe's Beating Cancer Plan - SoHO legislation - Sustainable Development Goals - EU4Health - Critical Medicines Act - EU Biotech Act - EU Competitiveness agenda - Sustainability and Green policies
Communication Activities
Organisation of dedicated policy events and policy communications campaigns aimed at raising awareness of HIV, Oncology and Advanced Therapies at EU-level. Participation in similar events and campaigns organised by multi-stakeholder initiatives and partner organisations. Organisation of site visits with EU policymakers to production facilities. Sponsorship of a media campaign and articles carried out and/or published by EU-based policy media.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
European Federation of Pharmaceutical Industries and Associations (EFPIA): http://www.efpia.eu European Confederation of Pharmaceutical Entrepreneurs (EUCOPE): http://www.eucope.org American Chamber of Commerce to the European Union (AMCHAM EU): http://www.amchameu.eu Alliance for Regenerative Medicine (ARM): https://alliancerm.org/
Organisation Members
HIV Outcomes - https://hivoutcomes.eu/ HIV Prevention Alliance - https://hivpreventionalliance.eu/ Transforming Breast Cancer Together - https://tbct.eu/
Additional Information
This estimate includes costs attributable to covered activities, including consulting fees, meeting costs and the pro-rata salary and travel costs of Gilead Sciences' staff involved in representation to the European institutions, based on the proportion of employee time spent on these activities. The two dedicated 100% FTEs started in September 2022 and are calculated pro-rata for the financial year of 2025.
Commissioner Meetings
No recorded meetings with EU commissioners.